[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.82.105. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Viewpoint
May 22, 2013

Advances in Regulatory Science at the Food and Drug Administration

Author Affiliations

Author Affiliations: Cardiovascular Health Research Unit, Departments of Medicine, Epidemiology, and Health Services, University of Washington, Seattle (Dr Psaty); Group Health Research Institute, Group Health Cooperative, Seattle (Dr Psaty); Department of Medicine, Stanford University, Stanford, California (Dr Goodman); and University of Liverpool, Liverpool, United Kingdom (Dr Breckenridge).

JAMA. 2013;309(20):2103-2104. doi:10.1001/jama.2013.4503

Since the Kefauver-Harris amendments of 1962, the US Food and Drug Administration (FDA) has required evidence of efficacy to approve a drug for marketing in the United States. For many years, information about benefits and risks was assembled at the time of approval, and if the benefits appeared to exceed the risks known at the time, the drug was deemed safe for approval. In practice, a drug that demonstrated efficacy according to the prespecified outcomes in the phase 3 trials was approved for marketing unless there was convincing evidence of a serious risk.

First Page Preview View Large
First page PDF preview
First page PDF preview
×